Patents by Inventor Serge Landry
Serge Landry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130150350Abstract: Compounds of formula (I) wherein m, R1, R2, R3, X and Y are defined herein, are useful as inhibitors of HIV replication.Type: ApplicationFiled: February 9, 2011Publication date: June 13, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Bruno Simoneau, Patrick Deroy, Lee Fader, Anne-Marie Faucher, Alexander Gagnon, Chantal Grand-Maitre, Stephen Kawai, Serge Landry, Jean-Francois Mercier, Jean Rancourt
-
Patent number: 8354429Abstract: Compounds of formula I: wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.Type: GrantFiled: September 11, 2008Date of Patent: January 15, 2013Assignee: Gilead Sciences, Inc.Inventors: Youla S. Tsantrizos, Murray D. Bailey, Francois Bilodeau, Rebekah J. Carson, Rene Coulombe, Lee Fader, Teddy Halmos, Stephen Kawai, Serge Landry, Steven LaPlante, Sebastien Morin, Mathieu Parisien, Marc-Andre Poupart, Bruno Simoneau
-
Publication number: 20110230465Abstract: Compounds of formula I: wherein X, R2, R3, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.Type: ApplicationFiled: September 16, 2010Publication date: September 22, 2011Applicant: BOEHRINGER INGLEHEIM INTERNATIONAL GMBHInventors: Timothy STAMMERS, Xavier BARBEAU, Pierre BEAULIEU, Megan BERTRAND-LAPERLE, Christian BROCHU, Paul J. EDWARDS, Pasquale FORGIONE, Cédrickx GODBOUT, Oliver HUCKE, Marc-André JOLY, Serge LANDRY, Olivier LEPAGE, Julie NAUD, Marc PESANT, Martin POIRIER, Maude POIRIER, Bounkham THAVONEKHAM
-
Patent number: 7642277Abstract: Disclosed herein are compounds of formula Ar1—X—W—Ar2 wherein Ar1 and Ar2 represent aryl groups characterized generally as aromatic heterocycles (e.g. imidazolyl or tetrazolyl) or carbocycles (e.g. phenyl or naphthalenyl); the aryl groups are optionally substituted or fused with other heterocycles or carbocycles; the aryl groups can bear substituents such as alkyl, halo or O-alkyl. X is a heteroatom, a valence bond or an optionally substituted divalent methylene, and W represents a spacer; typical spacers include divalent alkylene or alkylene-amido, -amido or -oxy radicals, which may optionally be substituted (e.g. hydroxyl or oxo). A typical compound is a derivative of 2-(N-napthalenyltetrazolylthio)-N-(2-nitrophenyl)acetamide. The compounds have inhibitory activity against Wild Type and single or double mutant strains of HIV.Type: GrantFiled: November 21, 2003Date of Patent: January 5, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Bruno Simoneau, Anne-Marie Faucher, Serge Landry, Jeffrey O'Meara, Bounkham Thavonekham, Christiane Yoakim
-
Publication number: 20090143370Abstract: Compounds of formula (I): wherein Ar, X, R1, R2, R3 and R4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.Type: ApplicationFiled: February 3, 2009Publication date: June 4, 2009Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Patrick DeROY, Anne-Marie FAUCHER, Alexandre GAGNON, Serge LANDRY, Sebastien MORIN, Jeffrey O'MEARA, Bruno SIMONEAU, Bounkham THAVONEKHAM, Christiane YOAKIM
-
Patent number: 7517998Abstract: Compounds of formula (I): wherein Ar, X, R1, R2, R3 and R4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.Type: GrantFiled: May 24, 2005Date of Patent: April 14, 2009Assignee: Boehringer Ingelheim International GmbHInventors: Patrick Deroy, Anne-Marie Faucher, Alexandre Gagnon, Serge Landry, Sebastien Morin, Jeffrey O'Meara, Bruno Simoneau, Bounkham Thavonekham, Christiane Yoakim
-
Patent number: 7323567Abstract: Compounds or enantiomers of formula (I) or a salt thereof: wherein R1, R2, R3, R4 and R5 are as defined herein, are useful for the manufacture of a medicament for the treatment or prevention of respiratory syncytial virus infection in a mammal.Type: GrantFiled: October 28, 2004Date of Patent: January 29, 2008Assignee: Boehringer Ingelheim (Canada) Ltd.Inventors: Bruno Simoneau, Josee Bordeleau, Gulrez Fazal, Serge Landry, Steve Mason, Jean Rancourt
-
Publication number: 20070225317Abstract: Compounds or enantiomers of formula (I) or a salt thereof: wherein R1, R2, R3, R4 and R5 are as defined herein, are useful for the manufacture of a medicament for the treatment or prevention of respiratory syncytial virus infection in a mammal.Type: ApplicationFiled: May 17, 2007Publication date: September 27, 2007Inventors: Bruno SIMONEAU, Josee BORDELEAU, Gulrez FAZAL, Serge LANDRY, Steve MASON, Jean RANCOURT
-
Publication number: 20050282907Abstract: Compounds of formula (I): wherein Ar, X, R1, R2, R3 and R4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.Type: ApplicationFiled: May 24, 2005Publication date: December 22, 2005Applicant: Boehringer Ingelheim International GmbHInventors: Patrick Deroy, Anne-Marie Faucher, Alexandre Gagnon, Serge Landry, Sebastien Morin, Jeffrey O'Meara, Bruno Simoneau, Bounkham Thavonekham, Christiane Yoakim
-
Publication number: 20050239814Abstract: Compounds or enantiomers of formula (I) or a salt thereof: wherein R1, R2, R3, R4 and R5 are as defined herein, are useful for the manufacture of a medicament for the treatment or prevention of respiratory syncytial virus infection in a mammal.Type: ApplicationFiled: October 28, 2004Publication date: October 27, 2005Applicant: Boehringer Ingelheim (Canada) Ltd.Inventors: Bruno Simoneau, Josee Bordeleau, Gulrez Fazal, Serge Landry, Steve Mason, Jean Rancourt
-
Publication number: 20050054639Abstract: Disclosed herein are compounds of formula Ar1—X—W—Ar2 wherein Ar1 and Ar2 represent aryl groups characterized generally as aromatic heterocycles (e.g. imidazolyl or tetrazolyl) or carbocycles (e.g. phenyl or naphthalenyl); the aryl groups are optionally substituted or fused with other heterocycles or carbocycles; the aryl groups can bear substituents such as alkyl, halo or O-alkyl. X is a heteroatom, a valence bond or an optionally substituted divalent methylene, and W represents a spacer; typical spacers include divalent alkylene or alkylene-amido, -amido or -oxy radicals, which may optionally be substituted (e.g. hydroxyl or oxo). A typical compound is a derivative of 2-(N-napthalenyltetrazolylthio)-N-(2-nitrophenyl)acetamide. The compounds have inhibitory activity against Wild Type and single or double mutant strains of HIV.Type: ApplicationFiled: November 21, 2003Publication date: March 10, 2005Applicant: Boehringer Ingelheim International GmbHInventors: Bruno Simoneau, Anne-Marie Faucher, Serge Landry, Jeffrey O'Meara, Bounkham Thavonekham, Christiane Yoakim
-
Patent number: 6806265Abstract: Compounds represented by formula I: wherein R2 is selected from the group consisting of H, (C1-4)alkyl, halo, haloalkyl, OH, (C1-6)alkoxy, NH(C1-4alkyl) or N(C1-4alkyl)2; R4 is H or Me; R5 is H or Me; R11 is H, (C1-4)alkyl, (C3-4)cycloalkyl and (C1-4)alkyl-(C3-4)cycloalkyl; A is a connecting chain of (C1-3)alkyl; B is O or S; n is 0 or 1; wherein when n is 0: Ring C is 6- or 10-membered aryl or 5- or 6-membered heterocycle having from 1 to 4 heteroatoms selected from the group consisting of O, N, and S, said aryl and said heterocycle being optionally substituted; and E is CONR12R13; CONHNR14R15; NR16COR17; NR18SO2(C1-6)alkyl; SO2NR19R20; or SO2R21; or when n is 1: Ring C is as defined above and E is a single bond or a connecting group; and Ring D is 6- or 10-membered aryl or 5- or 6-membered heterocycle having from 1 to 4 heteroatoms selected from the group consisting of O, N, and S, said aryl and said heterocycle being optionally substituted with from 1 to 5 substituents; or a salt orType: GrantFiled: May 6, 2003Date of Patent: October 19, 2004Assignee: Boehringer Ingelheim International GmbHInventors: Bruno Simoneau, Serge Landry, Eric Malenfant, Julie Naud, Jeffrey O'Meara, Bounkham Thavonekham, Christiane Yoakim
-
Publication number: 20040006071Abstract: Compounds represented by formula I: 1Type: ApplicationFiled: May 6, 2003Publication date: January 8, 2004Applicant: Boehringer Ingelheim International GmbHInventors: Bruno Simoneau, Serge Landry, Eric Malenfant, Julie Naud, Jeffrey O'Meara, Bounkham Thavonekham, Christiane Yoakim